var data={"title":"Amantadine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amantadine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5604?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amantadine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amantadine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=amantadine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amantadine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50907068\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Influenza Update</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Centers for Disease Control and Prevention (CDC) is reporting a significant increase in influenza activity over recent weeks, with influenza A(H3N2) viruses predominating. Past A(H3N2) virus-predominant influenza seasons have been associated with more hospitalizations and deaths in persons 65 years of age and older, as well as in young children, compared to other age groups. Influenza vaccine effectiveness has also been generally lower against A (H3N2) viruses than against influenza A (H1N1) pdm09 or influenza B viruses. Last influenza season, vaccine effectiveness against circulating A (H3N2) viruses was estimated to be 32% in the US and is expected to be similar this season if the same A (H3N2) viruses continue to predominate. Influenza activity was high in the Southern Hemisphere in 2017 and preliminary data from Australia suggest overall vaccine effectiveness of 33% but only 10% against A (H3N2) viruses, making the use of antiviral medications for treatment of influenza, in addition to preventive vaccination, even more important.</p>\n        <p style=\"text-indent:0em;\">The CDC has also issued a health advisory stating that all hospitalized patients, patients with severe, complicated, or progressive illness (including outpatients), and all high-risk patients (including pediatric patients younger than 2 years; adults 65 years and older; patients with certain chronic illnesses or neurologic or neurodevelopmental conditions; immunosuppressed patients; women who are pregnant or postpartum (within 2 weeks of delivery); patients younger than 19 years of age receiving long term aspirin therapy; American Indians/Alaska Natives; patients with BMI of 40 or more; and residents of nursing homes or other chronic-care facilities) with suspected or confirmed influenza should be treated as soon as possible with a neuraminidase inhibitor antiviral (eg, oseltamivir, peramivir, zanamivir). Adamantanes (eg, amantadine, rimantadine) are not currently recommended for treatment or prophylaxis of influenza A because of high levels of resistance. Antivirals for influenza work best when initiated within 48 hours of illness onset; however, clinical benefit has been observed even when treatment is initiated later in some patients.</p>\n        <p style=\"text-indent:0em;\">Further information is available at <a target=\"_blank\" href=\"https://emergency.cdc.gov/han/han00409.asp&amp;token=/XpciKoGXD/NBcI56myByIrj6XDzXmi2bFm6I7VYATsTAoPzpN4M+ut5dGKrD6OM&amp;TOPIC_ID=8508\" target=\"_blank\">https://emergency.cdc.gov/han/han00409.asp</a> and <a target=\"_blank\" href=\"https://www.cdc.gov/flu/weekly/summary.htm&amp;token=R4Uiw8/bmPVaqNHRDqpXLOtzxb+vTZhOOrHrvoZzklFBp7r1xCTELF4KBDcLrJouICpPDwRTIgOkmOCDxEXvOQ==&amp;TOPIC_ID=8508\" target=\"_blank\">https://www.cdc.gov/flu/weekly/summary.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50642731\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Gocovri</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132715\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anti-Parkinson Agent, Dopamine Agonist;</li>\n      <li>\n        Antiviral Agent;</li>\n      <li>\n        Antiviral Agent, Adamantane</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132679\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note:</b> Osmolex ER tablets: FDA approved February 2018; anticipated availability is currently unknown. Dosing for Osmolex ER differs from Gocovri extended release capsules; monograph edits for Osmolex ER are pending.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Influenza A treatment/prophylaxis:</b> <b>Note:</b> Due to issues of resistance, amantadine is no longer recommended for the treatment or prophylaxis of influenza A (CDC 2011). Please refer to the current ACIP recommendations. The following is based on the manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Influenza A treatment:</i> Immediate release: Oral: 200 mg once daily <b>or</b> 100 mg twice daily (may be preferred to reduce CNS effects); <b>Note:</b> Initiate within 24 to 48 hours after onset of symptoms; continue for 24 to 48 hours after symptom resolution (duration of therapy is generally 5 days [CDC 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Influenza A prophylaxis:</i> Immediate release: Oral: 200 mg once daily <b>or</b> 100 mg twice daily (may be preferred to reduce CNS effects). <b>Note:</b> Continue prophylaxis throughout the peak influenza activity in the community or throughout the entire influenza season in patients who cannot be vaccinated. Development of immunity following vaccination takes ~2 weeks; amantadine therapy should be considered for high-risk patients from the time of vaccination until immunity has developed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Drug-induced extrapyramidal symptoms:</b> Immediate release: Oral: 100 mg twice daily; may increase to 300 mg/day in divided doses, if needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parkinson disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release (monotherapy or as an adjunct to dopaminergic medications): Oral: Initial: 137 mg once daily; after 1 week, increase to usual dose of 274 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Oral: Usual dose: 100 mg twice daily as monotherapy; may increase to 400 mg/day in divided doses, if needed, with close monitoring. <b>Note:</b> Patients with a serious concomitant illness or those receiving high doses of other antiparkinson drugs should be started at 100 mg once daily; may increase to 100 mg twice daily, if needed, after one to several weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chorea of Huntington disease (off-label use):</b> Immediate release: Oral:  100 mg 3 to 4 times daily. Additional data may be necessary to further define the role of amantadine in this condition (Armstrong 2012; O'Suilleabhain 2003; Verhagen 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple sclerosis-related fatigue (off-label use):</b> Immediate release: Oral: 100 mg twice daily. Additional data may be necessary to further define the role of amantadine in this condition (Ledinek 2013; Shaygannejad 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Restless legs syndrome (off-label use):</b> Immediate release: Oral: Initial: 100 mg daily; increase by 100 mg every 3 to 5 days based on response and tolerability up to 300 mg/day in 1 to 3 divided doses. Additional data may be necessary to further define the role of amantadine in this condition (Evidente 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traumatic brain injury (off-label use):</b> Immediate release: Oral: Initial: 100 mg twice daily (morning and afternoon); may increase total daily dose by 100 mg every week based on response and tolerability up to 200 mg twice daily. Additional data may be necessary to further define the role of amantadine in this condition (Giacino 2012; Hammond 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Discontinuation of therapy: </b>Do not discontinue abruptly. For patients who have taken the extended-release capsule for more than 4 weeks, reduce dose by half for 1 week before discontinuing, if possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132695\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=amantadine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amantadine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Influenza A treatment/prophylaxis:</b> Children and Adolescents: Oral: <b>Note:</b> Due to issues of resistance, amantadine is no longer recommended for the treatment or prophylaxis of influenza A (CDC 2011). Please refer to the current ACIP recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Influenza A treatment (CDC 2011): </i>Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 9 years: 5 mg/kg/day in 2 divided doses (manufacturer's range: 4.4 to 8.8 mg/kg/day); maximum dose: 150 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;10 years and &lt;40 kg: 5 mg/kg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;10 years and &ge;40 kg: 100 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Initiate within 24 to 48 hours after onset of symptoms; continue for 24 to 48 hours after symptom resolution (duration of therapy is generally 5 days)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Influenza A prophylaxis:</i> Immediate release: Refer to &quot;Influenza A treatment&quot; dosing. <b>Note:</b> Continue prophylaxis throughout the peak influenza activity in the community or throughout the entire influenza season in patients who cannot be vaccinated. Development of immunity following vaccination takes ~2 weeks; amantadine therapy should be considered for high-risk patients from the time of vaccination until immunity has developed. For children &lt;9 years receiving influenza vaccine for the first time, amantadine prophylaxis should continue for 6 weeks (4 weeks after the first dose and 2 weeks after the second dose).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Discontinuation of therapy: </b>Do not discontinue abruptly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132680\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Drug-induced extrapyramidal symptoms/Parkinson disease: </b>Refer to adult dosing; some patients tolerate the immediate-release formulations better when administered in 2 divided daily doses (to avoid adverse neurologic reactions).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Influenza A treatment/prophylaxis</b>: Immediate release: Oral: 100 mg once daily. <b>Note:</b> Due to issues of resistance, amantadine is no longer recommended for the treatment or prophylaxis of influenza A (CDC 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Discontinuation of therapy: </b>Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132681\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;60 mL/minute/1.73 m<sup>2</sup>: No adjustment needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 59 mL/minute/1.73 m<sup>2</sup>: Initial: 68.5 mg once daily; after 1 week increase to 137 mg once daily if needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15 to 29 mL/minute/1.73 m<sup>2</sup>: 68.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;15 mL/minute/1.73 m<sup>2</sup> (ESRD): Use contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Inefficiently dialyzed; use is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 50 mL/minute: 200 mg on day 1, then 100 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15 to 29 mL/minute: 200 mg on day 1, then 100 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;15 mL/minute: 200 mg every 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: 200 mg every 7 days (inefficiently dialyzed)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis: No supplemental dose is needed (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy: 100 mg once daily or every other day (Aronoff 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671485\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132650\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gocovri: 68.5 mg, 137 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/5 mL (10 mL, 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132635\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51128489\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Osmolex ER tablets: FDA approved February 2018; anticipated availability is currently unknown. Information pertaining to this product within the monograph is pending revision. Consult the prescribing information for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50815269\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Extended-release capsule: Administer at bedtime with or without food. Swallow whole; do not crush, chew or divide capsules. If needed, sprinkle entire contents on a small amount (teaspoonful) of soft food, such as applesauce, and administer immediately without chewing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132653\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Drug-induced extrapyramidal symptoms (immediate release only):</b> Treatment of drug-induced extrapyramidal symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Influenza A prophylaxis (immediate release only):</b> Chemoprophylaxis against signs and symptoms of influenza A virus infection; also refer to current Advisory Committee on Immunization Practices (ACIP) guidelines for recommendations during current influenza season.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Influenza A treatment (immediate release only): </b>Treatment of uncomplicated respiratory tract illness caused by influenza A virus strains; also refer to current ACIP guidelines for recommendations during current influenza season.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parkinson disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Treatment of dyskinesia in patients with Parkinson disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Treatment of idiopathic Parkinson disease (paralysis agitans), postencephalitic parkinsonism, parkinsonism in association with cerebral arteriosclerosis, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25816118\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chorea of Huntington disease; Multiple sclerosis&ndash;related fatigue; Restless legs syndrome; Traumatic brain injury</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132723\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amantadine may be confused with amiodarone, raNITIdine, riMANTAdine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Symmetrel may be confused with Synthroid</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132642\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Orthostatic hypotension (&le;29%; may be more common in men), presyncope (&le;29%), syncope (&le;29%), peripheral edema (1% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (&le;29%), delusions (&le;25%), hallucination (&le;25%), illusion (&le;25%), paranoia (&le;25%), falling (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (1% to 16%; may be more common in women), constipation (1% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Livedo reticularis (1% to 6%; may be more common in women)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (5% to 10%), anxiety (1% to 7%), depression (1% to 6%), headache (1% to 6%), abnormal dreams (1% to 5%; may be more common in women), agitation (1% to 5%), ataxia (1% to 5%; may be more common in men and adults &ge;65 years old), confusion (1% to 5%), drowsiness (1% to 5%), fatigue (1% to 5%), irritability (1% to 5%), nervousness (1% to 5%), dyschromia (3%), dystonia (3%), apathy (2%), suicidal ideation (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (5% to 10%; may be more common in women), decreased appetite (6%), anorexia (1% to 5%), diarrhea (1% to 5%), vomiting (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (10%), benign prostatic hypertrophy (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Joint swelling (3%), muscle spasm (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (4%), cataract (3%; may be more common in women), xerophthalmia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dry nose (1% to 5%), cough (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal gait, abnormality in thinking, acute respiratory tract failure, aggressive behavior, agranulocytosis, amnesia, anaphylaxis, cardiac arrhythmia (including malignant arrhythmias), cardiac failure, coma, corneal edema, decreased libido, decreased visual acuity, delirium, diaphoresis, dysphagia, dyspnea, eczema, edema, EEG pattern changes, euphoria, fever, hyperkinesia, hypersensitivity reaction, hypertension, hypertonia, hypokinesia, hypotension, impulse control disorder, increased blood urea nitrogen, increased creatine phosphokinase, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased libido, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, increased serum creatinine, keratitis, leukocytosis, leukopenia, mania, mydriasis, neuroleptic malignant syndrome (associated with dosage reduction or abrupt withdrawal of amantadine), neutropenia, oculogyric crisis, optic nerve palsy, paresthesia, pathological gambling, pruritus, psychosis, pulmonary edema, seizure, skin photosensitivity, skin rash, slurred speech, stupor, tachycardia, tachypnea, tremor, urinary retention, visual disturbance (including punctate subepithelial or other corneal opacity), weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132656\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to amantadine or any component of the formulation; end-stage renal disease (CrCl &lt;15 mL/minute/1.73 m<sup>2</sup>) (extended release only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132639\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving). Patients taking amantadine for Parkinson disease have reported falling asleep while engaged in activities of daily living, sometimes without warning. Patients with a concomitant sleep disorder may be at a greater risk. There is insufficient information that dose reduction will eliminate episodes of falling asleep or daytime somnolence.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Impulse control disorders: Dopamine agonists used for Parkinson disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), urges to spend money, and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions, and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Melanoma: Risk for melanoma development is increased in Parkinson disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome: Has been associated with neuroleptic malignant syndrome (associated with dose reduction or abrupt discontinuation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Visual and auditory hallucinations, delusions, illusions, and paranoia were reported in clinical trials; monitor for the occurrence of these symptoms especially at initiation and after dose increases. Use with caution in patients with uncontrolled psychosis or severe psychoneurosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation/depression: There have been reports of suicidal ideation/attempt and depression in patients with and without a history of psychiatric illness. May exacerbate mental problems in patients with a history of mental illness.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with heart failure, peripheral edema, or orthostatic hypotension; dizziness, syncope, orthostatic hypotension, presyncope, postural dizziness, and hypotension have been reported in clinical trials. Dosage reduction may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Eczema: Use with caution in patients with a history of recurrent and eczematoid dermatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Avoid in untreated angle closure glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; rarely, reversible elevations in transaminases have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Influenza A: Appropriate use: Consult current guidelines. Due to increased resistance, the ACIP has recommended that rimantadine and amantadine no longer be used for the treatment or prophylaxis of influenza A in the United States until susceptibility has been re-established (CDC 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage reduction recommended. Use of the extended-release capsule is contraindicated in end-stage renal disease (CrCl &lt;15 mL/minute/1.73 m<sup>2</sup>).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more susceptible to CNS effects (using 2 divided daily doses of immediate-release products may minimize this effect). These patients may require dosage reductions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tolerance: Tolerance has also been reported with long-term use (Zubenko1984).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal syndrome: May cause agitation, anxiety, delirium, delusions, depression, hallucinations, paranoia, parkinsonian crisis, slurred speech, or stupor. Upon discontinuation of amantadine therapy, gradually taper dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298728\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OCT2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132644\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8508&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of Amantadine. Alcohol may also cause dose-dumping for at least one extended-release amantadine product.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alkalinizing Agents: May increase the serum concentration of Amantadine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: Amantadine may enhance the anticholinergic effect of Anticholinergic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (First Generation [Typical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: Anti-Parkinson Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May increase the serum concentration of Amantadine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Systemic): Amantadine may enhance the anticholinergic effect of Glycopyrrolate (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: NMDA Receptor Antagonists may enhance the adverse/toxic effect of Memantine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propiverine: May enhance the adverse/toxic effect of Amantadine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urinary Acidifying Agents: May decrease the serum concentration of Amantadine.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132646\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132660\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies and teratogenic events have been observed in humans (case reports) (Seier 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When treatment for Parkinson disease is needed, agents other than amantadine are recommended in pregnant women (Seier 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother. Other agents are currently recommended for the treatment or prophylaxis influenza in pregnant women and women up to 2 weeks postpartum. Appropriate antiviral agents are currently recommended as an adjunct to vaccination and should not be used as a substitute for vaccination in pregnant women (CDC 2011; CDC 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11313487\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Amantadine is present in breast milk. Amantadine may alter breast milk production or excretion. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132648\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function (baseline and as clinically indicated), mental status including psychosis, depression and suicidality, blood pressure (as clinically indicated)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132638\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiviral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The mechanism of amantadine&rsquo;s antiviral activity has not been fully elucidated. It appears to primarily prevent the release of infectious viral nucleic acid into the host cell by interfering with the transmembrane domain of the viral M2 protein. Amantadine is also known to prevent viral assembly during replication. Amantadine inhibits the replication of influenza A virus isolates from each of the subtypes (ie, H1N1, H2N2 and H3N2), but has very little or no activity against influenza B virus isolates.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parkinson disease:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The exact mechanism of amantadine in the treatment of Parkinson disease and drug-induced extrapyramidal symptoms is not known. Data from early animal studies suggest that amantadine may have direct and indirect effects on dopamine neurons; however, recent studies have demonstrated that amantadine is a weak, noncompetitive NMDA receptor antagonist. Although amantadine has not been shown to possess direct anticholinergic activity, clinically, it exhibits anticholinergic-like side effects (dry mouth, urinary retention, and constipation).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132655\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Antidyskinetic: Within 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Normal: 3 to 8 L/kg; Renal failure: 5.1 &plusmn; 0.2 L/kg (Aoki 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Normal renal function: ~67%; Hemodialysis: ~59% (Aoki 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not appreciable; small amounts of an acetyl metabolite identified</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Immediate release: 86% to 94% (Aoki 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Normal renal function: 16 &plusmn; 6 hours (9 to 31 hours); Healthy, older (&ge;60 years) males: 29 hours (range: 20 to 41 hours) (Aoki 1988); End-stage renal disease: 8 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Extended release: 12 hours (mean; range: 6 to 20 hours); immediate release: 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80% to 90% unchanged) by glomerular filtration and tubular secretion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132659\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Gocovri Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">68.5 mg (60): $2,850.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">137 mg (60): $2,850.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Amantadine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $201.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Amantadine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (473 mL): $72.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Amantadine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $228.33</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132661\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actison (AR, PE);</li>\n      <li>Amadin (BD);</li>\n      <li>Amanda (TW);</li>\n      <li>Amandin (HK, TW);</li>\n      <li>Amandine (UY);</li>\n      <li>Amanta (KR);</li>\n      <li>Amantadin (EE);</li>\n      <li>Amantan (LU);</li>\n      <li>Amantin (BD);</li>\n      <li>Amantix (CO, PL);</li>\n      <li>Amantrel (IN);</li>\n      <li>Amantril (BD);</li>\n      <li>Amantyn (UA);</li>\n      <li>Ampakine (AR, PE);</li>\n      <li>Atadin (TW);</li>\n      <li>Atarin (CL);</li>\n      <li>Atenergine (JP);</li>\n      <li>Enzil (HK, TW);</li>\n      <li>Hofcomant (AT, FI);</li>\n      <li>Influ (BD, TW);</li>\n      <li>Influ-A (IL);</li>\n      <li>Kinestrel (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Lysovir (GB);</li>\n      <li>Mantadan (IT);</li>\n      <li>Mantadix (FR, LU);</li>\n      <li>Mantidan (BR);</li>\n      <li>Mantra (CL);</li>\n      <li>Midantan (RU);</li>\n      <li>Neomidantan (LV, RO, RU);</li>\n      <li>Neomidantin (UA);</li>\n      <li>Parkadina (PT);</li>\n      <li>Parkintrel (KR);</li>\n      <li>PK Merz (CU);</li>\n      <li>PK-Merz (AT, BF, BG, BH, BJ, CH, CI, CL, CR, CY, CZ, DE, DO, EE, ET, GH, GM, GN, GT, HK, HN, HR, HU, IL, IQ, IR, JO, KE, KR, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, OM, PA, PH, PK, PY, QA, RU, SA, SC, SD, SK, SL, SN, SV, SY, TN, TR, TW, TZ, UA, UG, YE, ZM, ZW);</li>\n      <li>Prayanol (CL);</li>\n      <li>Symadin (ZA);</li>\n      <li>Symmetrel (AE, AU, BH, CH, CY, EG, GR, HK, HR, IE, IQ, IR, JP, LB, LY, MT, NL, NO, NZ, OM, SG, SY, YE, ZA);</li>\n      <li>Tregor (DE);</li>\n      <li>Viergyt-K (RO);</li>\n      <li>Viregyt (HU);</li>\n      <li>Viregyt K (PL);</li>\n      <li>Viregyt-K (BG, CZ);</li>\n      <li>Virofral (DK);</li>\n      <li>Virosol (AR, PE);</li>\n      <li>Zintergia (CO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allen RM, &ldquo;Palliative Treatment of Tardive Dyskinesia With Combination of Amantadine-Neuroleptic Administration,&rdquo; <i>Biol Psychiatry</i>, 1982, 17(6):719-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/6179548/pubmed\" target=\"_blank\" id=\"6179548\">6179548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alphs L and Davis JM, &ldquo;Noncatecholaminergic Treatments of Tardive Dyskinesia,&rdquo; <i>J Clin Psychopharmacol</i>, 1982, 2(6):380-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/6129267/pubmed\" target=\"_blank\" id=\"6129267\">6129267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amantadine hydrochloride capsules [prescribing information]. High Point, NC: Banner Life Sciences LLC; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amantadine hydrochloride oral solution [prescribing information]. Farmville, NC: CMP Pharma Inc; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amantadine hydrochloride tablets [prescribing information]. Parsippany, NJ: Actavis Pharma Inc.; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aoki FY and Sitar DS, &ldquo;Amantadine Kinetics in Healthy Elderly Men: Implications for Influenza Prevention,&rdquo; <i>Clin Pharmacol Ther</i>, 1985, 37(2):137-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/3967456/pubmed\" target=\"_blank\" id=\"3967456\">3967456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aoki FY and Sitar DS, &ldquo;Clinical Pharmacokinetics of Amantadine Hydrochloride,&rdquo; <i>Clin Pharmacokinet</i>, 1988, 14(1):35-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/3280212/pubmed\" target=\"_blank\" id=\"3280212\">3280212</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22815556\"></a>Armstrong MJ, Miyasaki JM; American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2012;79(6):597-603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/22815556/pubmed\" target=\"_blank\" id=\"22815556\">22815556</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24963407\"></a>Asano M, Finlayson ML. Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. <i>Mult Scler Int</i>. 2014;2014:798285.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/24963407/pubmed\" target=\"_blank\" id=\"24963407\">24963407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22851801\"></a>Aurora RN, Kristo DA, Bista SR, et al; American Academy of Sleep Medicine. The treatment of restless legs syndrome and periodic limb movement disorder in adults&mdash;an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. <i>Sleep</i>. 2012;35(8):1039-1062.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/22851801/pubmed\" target=\"_blank\" id=\"22851801\">22851801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borison RL, &ldquo;Amantadine in the Management of Extrapyramidal Side Effects,&rdquo; <i>Clin Neuropharmacol</i>, 1983, 6(Suppl 1):57-63.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21975581\"></a>Burgunder JM, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease. Version 2. <i>PLoS Curr</i>. 2011;3:RRN1260.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/21975581/pubmed\" target=\"_blank\" id=\"21975581\">21975581</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Influenza Division, National Center for Immunization and Respiratory Diseases. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza --- Recommendations of the Advisory Committee on Immunization Practices (ACIP),&quot; <i>MMWR Surveill Summ</i>, 2011, 60(1):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/21248682/pubmed\" target=\"_blank\" id=\"21248682\">21248682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &quot;Interim Guidance: Considerations Regarding 2009 Novel H1N1 Flu Virus in Intrapartum and Postpartum Hospital Settings,&quot; Available at <a href=\"http://www.cdc.gov/h1n1flu/guidance/obstetric.htm\" target=\"_blank\">http://www.cdc.gov/h1n1flu/guidance/obstetric.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/12755288/pubmed\" target=\"_blank\" id=\"12755288\">12755288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. <a href=\"http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm\" target=\"_blank\">http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm</a>. Published March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Drugs for Non-HIV Viral Infections,&rdquo; <i>Med Lett Drugs Ther</i>, 2002, 44(1123):9-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/11828264/pubmed\" target=\"_blank\" id=\"11828264\">11828264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10752586\"></a>Evidente VG, Adler CH, Caviness JN, Hentz JG, Gwinn-Hardy K. Amantadine is beneficial in restless legs syndrome. <i>Mov Disord</i>. 2000;15(2):324-327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/10752586/pubmed\" target=\"_blank\" id=\"10752586\">10752586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Factor SA, &ldquo;Current Status of Symptomatic Medical Therapy in Parkinson&rsquo;s Disease,&rdquo; <i>Neurotherapeutics</i>, 2008, 5(2):164-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/18394561/pubmed\" target=\"_blank\" id=\"18394561\">18394561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22375973\"></a>Giacino JT, Whyte J, Bagiella E, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. <i>N Engl J Med</i>. 2012;366(9):819-826.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/22375973/pubmed\" target=\"_blank\" id=\"22375973\">22375973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gocovri (amantadine hydrochloride) [prescribing information]. Emeryville, CA: Adams Pharma LLC; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24263176\"></a>Hammond FM, Bickett AK, Norton JH, Pershad R. Effectiveness of amantadine hydrochloride in the reduction of chronic traumatic brain injury irritability and aggression. <i>J Head Trauma Rehabil</i>. 2014;29(5):391-399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/24263176/pubmed\" target=\"_blank\" id=\"24263176\">24263176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koller WC, Silver DE, and Lieberman A, &ldquo;An Algorithm for the Management of Parkinson's Disease,&rdquo; <i>Neurology</i>, 1994, 44(12 Suppl 10):1-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/8290041/pubmed\" target=\"_blank\" id=\"8290041\">8290041</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ledinek AH, Sajko MC, Rot U. Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis&mdash;result of a pilot randomized, blind study. <i>Clin Neurol Neurosurg</i>. 2013;115(suppl 1):S86-s89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/24321164/pubmed\" target=\"_blank\" id=\"24321164\">24321164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Louie JK, Jamieson DJ, Rasmussen SA. 2009 pandemic influenza A (H1N1) virus infection in postpartum women in California. <i>Am J Obstet Gynecol</i>. 2011;204(2):144.e1-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/21074132/pubmed\" target=\"_blank\" id=\"21074132\">21074132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Merigan KS, and Browning RG, &ldquo;Despiramine and Amantadine Causing False-Positive Urine Test for Amphetamine,&rdquo; <i>Ann Emerg Med</i>, 1993, 22(12):1927-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/8239121/pubmed\" target=\"_blank\" id=\"8239121\">8239121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller KS and Miller JM, &ldquo;Toxic Effects of Amantadine in Patients With Renal Failure,&rdquo; <i>Chest</i>, 1994, 105(5):1630.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molina JA, S&agrave;inz-Artiga MJ, Fraile A, et al, &ldquo;Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,&rdquo; <i>Mov Disord</i>, 2000, 15(5):869-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/11009192/pubmed\" target=\"_blank\" id=\"11009192\">11009192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      National Institute for Health and Care Excellence (NICE). Multiple sclerosis in adults: management. NICE clinical guideline CG186. London, UK: National Institute for Health and Care Excellence; October 2014. https://www.nice.org.uk/guidance/cg186. Accessed July 18, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17020483\"></a>Neurobehavioral Guidelines Working Group, Warden DL, Gordon B, McAllister TW, et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. <i>J Neurotrauma</i>. 2006;23(10):1468-1501.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/17020483/pubmed\" target=\"_blank\" id=\"17020483\">17020483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12873857\"></a>O'Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. <i>Arch Neurol</i>. 2003;60(7):996-998.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/12873857/pubmed\" target=\"_blank\" id=\"12873857\">12873857</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poldinger W, &ldquo;Therapy of Extrapyramidal Side Effects, With Particular Reference to Persistent Dyskinesia and Lithium Tremor,&rdquo; <i>International Pharmacopsychiatry</i>, 1978, 13(4):230-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/32149/pubmed\" target=\"_blank\" id=\"32149\">32149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seier M, Hiller A. Parkinson's disease and pregnancy: An updated review. <i>Parkinsonism Relat Disord</i>. 2017;40:11-17. doi: 10.1016/j.parkreldis.2017.05.007.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/28506531/pubmed\" target=\"_blank\" id=\"28506531\">28506531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaygannejad V, Janghorbani M, Ashtari F, Zakeri H. Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. <i>Neurol Res</i>. 2012;34(9):854-858.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/22979982/pubmed\" target=\"_blank\" id=\"22979982\">22979982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Somani SK, Degelau J, Cooper SL, et al, &ldquo;Comparison of Pharmacokinetic and Safety Profiles of Amantadine 50- and 100-mg Daily Doses in Elderly Nursing Home Residents,&rdquo; <i>Pharmacotherapy</i>, 1991, 11(6):460-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/1771145/pubmed\" target=\"_blank\" id=\"1771145\">1771145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stange KC, Little DW, and Blatnik B, &ldquo;Adverse Reactions to Amantadine Prophylaxis of Influenza in a Retirement Home,&rdquo; <i>J Am Geriatr Soc</i>, 1991, 33(7):700-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strong DK, Eisenstat DD, Bryson SM, et al, &ldquo;Amantadine Neurotoxicity in a Pediatric Patient With Renal Insufficiency,&rdquo; <i>DICP</i>, 1991, 25(11):1175-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/1763530/pubmed\" target=\"_blank\" id=\"1763530\">1763530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12221159\"></a>Verhagen Metman L, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. <i>Neurology</i>. 2002;59(5):694-699.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/12221159/pubmed\" target=\"_blank\" id=\"12221159\">12221159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weintraub D, Siderowf AD, Potenza MN, et al, &ldquo;Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,&rdquo; <i>Arch Neurol</i>, 2006, 63(7):969-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/16831966/pubmed\" target=\"_blank\" id=\"16831966\">16831966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zubenko GS, Barreira P, and Lipinski JF Jr, &ldquo;Development of Tolerance to the Therapeutic Effect of Amantadine on Akathisia,&rdquo; <i>J Clin Psychopharmacol</i>, 1984, 4(4):218-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-drug-information/abstract-text/6470196/pubmed\" target=\"_blank\" id=\"6470196\">6470196</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8508 Version 207.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50907068\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F50642731\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F132715\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F132679\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F132695\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F132680\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F132681\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671485\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F132650\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F132635\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F51128489\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50815269\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F132653\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25816118\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F132723\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F132642\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F132656\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F132639\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298728\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F132644\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F132646\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F132660\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11313487\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F132648\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F132638\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F132655\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F132659\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F132661\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8508|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amantadine-patient-drug-information\" class=\"drug drug_patient\">Amantadine: Patient drug information</a></li><li><a href=\"topic.htm?path=amantadine-pediatric-drug-information\" class=\"drug drug_pediatric\">Amantadine: Pediatric drug information</a></li></ul></div></div>","javascript":null}